Bao Lam

Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers

Luis A. Díaz, Aurélien Marabelle, T.W. Kim et al. · Annals of Oncology · 2017 · 66 citations

Medicine, Oncology, Molecular Oncology +8

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia

Catherine C. Smith, Mark J. Levis, Olga Frankfurt et al. · Blood Advances · 2020 · 47 citations · Full text

Medicine, Oncology, Pharmacology +13

KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).

Luis A. Díaz, Dung T. Le, Takayuki Yoshino et al. · Journal of Clinical Oncology · 2018 · 41 citations

Medicine, Immunology, Oncology +17

How does herd behaviour impact the purchase intention? Explore the moderating effect of risk aversion in the context of Vietnamese consumers

Minh Phạm, Nhu Kieu Thi Vo, Sang Sang Thi Tran et al. · Acta Psychologica · 2023 · 15 citations · Full text

Social Sciences, Marketing, Psychology +15

Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.

Luis A. Díaz, Dung T. Le, Takayuki Yoshino et al. · Journal of Clinical Oncology · 2017 · 11 citations

Medicine, Immunology, Oncology +17